1. Obata T, Goto Y, Kunisawa J, et al. Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis. Proc. Natl. Acad. Sci. 2010; 107: 7419–7424.
2. Johansson ME V, Phillipson M, Petersson J, et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Pnas 2008; 105: 15064–15069.
3. Lelouard H, Fallet M, De Bovis B, et al. Peyer’s patch dendritic cells sample antigens by extending dendrites through M cell-specific transcellular pores. Gastroenterology 2012; 142: 592–601.
4. Fujiyama Y & Andoh A. [Dysbiosis in inflammatory bowel disease]. Nihon Rinsho. 2012; 70 Suppl 1: 79–84.
5. Zheng D, Liwinski T & Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020; 30: 492–506.
6. Palmela C, Chevarin C, Xu Z, et al. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut 2018; 67: 574–587.
7. Small CL, Xing L, McPhee JB, et al. Acute Infectious Gastroenteritis Potentiates a Crohn’s Disease Pathobiont to Fuel Ongoing Inflammation in the Post-Infectious Period. PLoS Pathog. 2016; 12: e1005907.
8. Dreux N, Denizot J, Martinez-Medina M, et al. Point Mutations in FimH Adhesin of Crohn’s Disease-Associated Adherent-Invasive Escherichia coli Enhance Intestinal Inflammatory Response. PLoS Pathog. 2013; 9: e1003141.
9. Viladomiu M, Kivolowitz C, Abdulhamid A, et al. IgA-coated E. coli enriched in Crohn’s disease spondyloarthritis promote T H 17- dependent inflammation. Sci. Transl. Med. 2017; 9: eaaf9655.
10. Glasser A, Boudeau J, Barnich N, et al. Adherent Invasive Escherichia coli Strains from Patients with Crohn ’ s Disease Survive and Replicate within Macrophages without Inducing Host Cell Death Adherent Invasive Escherichia coli Strains from Patients with Crohn ’ s Disease Survive and Replicate. Infect. Immun. Immun 2001; 69: 5529–37.
11. Gonçalves P, Magro F & Martel F. Metabolic inflammation in inflammatory bowel disease: Crosstalk between adipose tissue and bowel. Inflamm. Bowel Dis. 2015; 21: 453–467.
12. Drouet M, Dubuquoy L, Desreumaux P, et al. Visceral fat and gut inflammation. Nutrition 2012; 28: 113–117.
13. Neurath MF. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 2014; 14: 329–342.
14. Scheele GA, Fukuoka SI & Freedman SD. Role of the GP2/THP family of GPI-anchored proteins in membrane trafficking during regulated exocrine secretion. Pancreas 1994; 9: 139–149.
15. Rindler MJ & Hoops TC. The pancreatic membrane protein GP-2 localizes specifically to secretory granules and is shed into the pancreatic juice as a protein aggregate. Eur. J. Cell Biol. 1990; 53: 154–163.
16. Fukuoka SL & Scheele G. Nucleotide sequence encoding the major glycoprotein (GP2) of rat pancreatic secretory (zymogen) granule membranes. Nucleic Acids Res. 1990; 18: 5900.
17. Yu S, Michie SA & Lowe AW. Absence of the major zymogen granule membrane protein, GP2, does not affect pancreatic morphology or secretion. J. Biol. Chem. 2004; 279: 50274–50279.
18. Pavlidis P, Komorowski L, Teegen B, et al. Diagnostic and clinical significance of Crohn’s disease-specific pancreatic anti-GP2 and anti- CUZD1 antibodies. Clin. Chem. Lab. Med. 2016; 54: 249–256.
19. Papp M, Sipeki N, Tornai T, et al. Rediscovery of the anti-pancreatic antibodies and evaluation of their prognostic value in a prospective clinical cohort of Crohn’s patients: The importance of specific target antigens [GP2 and CUZD1]. J. Crohn’s Colitis 2015; 9: 659–668.
20. Michaels MA, Jendrek ST, Korf T, et al. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn’s Disease. Inflamm. Bowel Dis. 2015; 21: 2864– 2872.
21. Shpoliansky M, Roggenbuck D, Pinsker M, et al. Antibodies Against Glycoprotein 2 Are Specific Biomarkers for Pediatric Crohn’s Disease. Dig. Dis. Sci. 2020; Online ahead of print. doi:10.1007/s10620-020- 06589-5.
22. Derer S, Brethack AK, Pietsch C, et al. Inflammatory Bowel Disease- associated GP2 Autoantibodies Inhibit Mucosal Immune Response to Adherent-invasive Bacteria. Inflamm. Bowel Dis. 2020; 26: 1856–1868.
23. Hao Y, Wang J, Feng N, et al. Determination of plasma glycoprotein 2 levels in patients with pancreatic disease. Arch. Pathol. Lab. Med. 2004; 128: 668–674.
24. Komorowski L, Teegen B, Probst C, et al. Autoantibodies against exocrine pancreas in Crohn’s disease are directed against two antigens: The glycoproteins CUZD1 and GP2. J. Crohn’s Colitis 2013; 7: 780– 790.
25. Terahara K, Yoshida M, Igarashi O, et al. Comprehensive gene expression profiling of Peyer’s patch M cells, villous M-like cells, and intestinal epithelial cells. J. Immunol. 2008; 180: 7840–7846.
26. Hase K, Kawano K, Nochi T, et al. Uptake through glycoprotein 2 of FimH + bacteria by M cells initiates mucosal immune response. Nature 2009; 462: 226–230.
27. Wood MB, Rios D & Williams IR. TNF-α augments RANKL-dependent intestinal M cell differentiation in enteroid cultures. Am. J. Physiol. - Cell Physiol. 2016; 311: C498–C507.
28. Yu S & Lowe AW. The pancreatic zymogen granule membrane protein, GP2, binds Escherichia coli type 1 Fimbriae. BMC Gastroenterol. 2009; 23: 58.
29. Ohno H & Hase K. Glycoprotein 2 (GP2) grabbing the fimH+ bacteria into m cells for mucosal immunity. Gut Microbes 2010; 1: 407–410.
30. Bates JM, Raffi HM, Prasadan K, et al. Tamm-Horsfall protein knockout mice are more prone to urinary tract infection. Kidney Int. 2004; 65: 791–797.
31. Pak J, Pu Y, Zhang ZT, et al. Tamm-Horsfall Protein Binds to Type 1 Fimbriated Escherichia coli and Prevents E. coli from Binding to Uroplakin Ia and Ib Receptors. J. Biol. Chem. 2001; 276: 9924–9930.
32. Cavallone D, Malagolini N, Monti A, et al. Variation of High Mannose Chains of Tamm-Horsfall Glycoprotein Confers Differential Binding to Type 1-fimbriated Escherichia coli. J. Biol. Chem. 2004; 279: 216–222.
33. Sato S, Kaneto S, Shibata N, et al. Transcription factor Spi-B- dependent and-independent pathways for the development of Peyer’s patch M cells. Mucosal Immunol. 2013; 6: 838–846.
34. Kerneis S, Bogdanova A, Colucci-Guyon E, et al. Cytosolic distribution of villin in M cells from mouse Peyer’s patches correlates with the absence of a brush border. Gastroenterology 1996; 110: 515–521.
35. Magnuson MA & Osipovich AB. Pancreas-specific Cre driver lines and considerations for their prudent use. Cell Metab 2013; 18: 9–20.
36. Chassaing B, Aitken JD, Malleshappa M, et al. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 2014; 104: 15.25.1–14.
37. Nochi T, Yuki Y, Matsumura A, et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen- specific immune responses. J. Exp. Med. 2007; 204: 2789–2796.
38. Kishikawa S, Sato S, Kaneto S, et al. Allograft inflammatory factor 1 is a regulator of transcytosis in M cells. Nat. Commun. 2017; 8: 1–10.
39. Azevedo-Pouly ACP, Elgamal OA & Schmittgen TD. RNA Isolation from Mouse Pancreas: A Ribonuclease-rich Tissue. J. Vis. Exp. 2014; 2: e51779.
40. Gout J, Pommier RM, Vincent DF, et al. Isolation and Culture of Mouse Primary Pancreatic Acinar Cells. J. Vis. Exp. 2013; 13: 50514.
41. Kim SW, Suda W, Kim S, et al. Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high- throughput pyrosequencing. DNA Res. 2013; 20: 241–253.
42. Okumura R, Kurakawa T, Nakano T, et al. Lypd8 promotes the segregation of flagellated microbiota and colonic epithelia. Nature 2016; 532: 117–121.
43. Fukuda S, Hase K & Ohno H. Application of a Mouse Ligated Peyer’s Patch Intestinal Loop Assay to Evaluate Bacterial Uptake by M cells. J. Vis. Exp. 2011; 17: 3225.
44. Laforest L, St-Jean P & Beaudoin A. A unique secretory behavior for GP2 in the exocrine pancreas. Biochem Biophys Res Commun. 1992; 184: 888–892.
45. Kimura S, Kishimoto A, Mutoh M, et al. GP2-expressing cells in the conjunctiva and tear ducts of mice: identification of a novel type of cells in the squamous stratified epithelium. Biomed. Res. 2015; 36: 263–272.
46. Kimura S, Nio-Kobayashi J, Kishimoto A, et al. The broad distribution of GP2 in mucous glands and secretory products. Biomed. Res. 2016; 37: 351–358.
47. Kiesler P, Fuss IJ & Strober W. Experimental models of inflammatory bowel diseases. Med. Hyg. (Geneve). 2001; 59: 241–248.
48. Pizarro TT, Arseneau KO, Bamias G, et al. Mouse models for the study of Crohn’s disease. Trends Mol. Med. 2003; 9: 218–222.
49. Freedman SD, Sakamoto K, Hospital BI, et al. Nonparallel secretion of GP-2 from exocrine pancreas implies luminal coupling between acinar and duct cells. Am. J. Physiol. 1994; 267: G40-51.
50. Zapata-Quintanilla LB, Palmeira P, Tino-De-Franco M, et al. Systemic antibody response to diarrheagenic Escherichia coli and LPS O111, O157 and O55 in healthy Brazilian adults. Scand. J. Immunol. 2006; 64: 661–667.
51. Blaschke M, Koepp R, Cortis J, et al. IL-6, IL-1β, and TNF-α only in combination influence the osteoporotic phenotype in Crohn’s patients via bone formation and bone resorption. Adv. Clin. Exp. Med. 2018; 27: 45–56.
52. Ding NS, Hart A & De Cruz P. Systematic review: Predicting and optimising response to anti-TNF therapy in Crohn’s disease - Algorithm for practical management. Aliment. Pharmacol. Ther. 2016; 43: 30–51.
53. Schmitt H, Billmeier U, Dieterich W, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease. Gut 2019; 65: 814–828.
54. Takahashi Y, Sato S, Kurashima Y, et al. Reciprocal Inflammatory Signaling Between Intestinal Epithelial Cells and Adipocytes in the Absence of Immune Cells. EBioMedicine 2017; 23: 34–45.
55. Kanaya T, Hase K, Takahashi D, et al. The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells. Nat. Immunol. 2012; 13: 729–736.
56. Nagashima K, Sawa S, Nitta T, et al. Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. Nat. Immunol. 2017; 18: 675–682.
57. Wang Y, Yin Y, Chen X, et al. Induction of Intestinal Th17 Cells by Flagellins From Segmented Filamentous Bacteria. Front. Immunol. 2019; 10: 485–498.
58. Sambasivarao S V. Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice. NIH Public Access 2013; 18: 1199–1216.
59. Jonathan M Rhodes. The role of Esherichia coli in inflammatory bowel disease. Gut 2007; 56: 610–2.
60. Munyaka PM, Rabbi MF, Khafipour E, et al. Acute dextran sulfate sodium (DSS)-induced colitis promotes gut microbial dysbiosis in mice. J. Basic Microbiol. 2016; 56: 986–998.
61. Kolenda R, Burdukiewicz M, Schiebel J, et al. Adhesion of Salmonella to pancreatic secretory granule membrane major glycoprotein GP2 of human and porcine origin depends on FimH sequence variation. Front. Microbiol. 2018; 9: 1–15.
62. Spaulding CN, Klein RD, Ruer S, et al. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature 2017; 546: 528–532.
63. Sauer MM, Jakob RP, Eras J, et al. Catch-bond mechanism of the bacterial adhesin FimH. Nat. Commun. 2016; 7: 10738.
64. Sivignon A, Yan X, Dorta DA, et al. Development of heptylmannoside- based glycoconjugate antiadhesive compounds against adherent- invasive escherichia coli bacteria associated with crohn’s disease. MBio 2015; 6: 1–9.
65. Alvarez Dorta D, Sivignon A, Chalopin T, et al. The Antiadhesive Strategy in Crohn′s Disease: Orally Active Mannosides to Decolonize Pathogenic Escherichia coli from the Gut. ChemBioChem 2016; 17: 936–952.
66. Atuma C, Strugala V, Allen A, et al. The adherent gastrointestinal mucus gel layer: Thickness and physical state in vivo. Am. J. Physiol. - Gastrointest. Liver Physiol. 2001; 280: 922–929.
67. Shun T, Tomohisa S & Takanori K. Intestinal immune response is regulated by gut microbe. Japanese J. Clin. Immunol. 2017; 40: 408– 415.
68. Galtier M, De Sordi L, Sivignon A, et al. Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn’s disease. J. Crohn’s Colitis 2017; 11: 840–847.
69. Jasdanwala S & Babyatsky M. Crohn’s disease and acute pancreatitis. A review of literature. Jop 2015; 16: 136–142.
70. Broide E, Dotan I, Weiss B, et al. Idiopathic pancreatitis preceding the diagnosis of inflammatory bowel disease is more frequent in pediatric patients. J. Pediatr. Gastroenterol. Nutr. 2011; 52: 714–717.
71. Martín-de-Carpi J, Moriczi M, Pujol-Muncunill G, et al. Pancreatic Involvement in Pediatric Inflammatory Bowel Disease. Front. Pediatr. 2017; 5: 1–5.
72. Lowe AW, Luthen RE, Wong SME, et al. The level of the zymogen granule protein GP2 is elevated in a rat model for acute pancreatitis. Gastroenterology 1994; 107: 1819–1827.
論文の公開元へ
